SCHEMBL7180550

SCHEMBL7180550

CC(C)C[P](=O)c1ccccc1C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
CTSS P25774 5/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
TAS2R14 Q9NYV8 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
CTSK P43235 2/20 0.34
P2RX7 Q99572 1/20 0.34
CTNNB1 P35222 1/20 0.34
WNT3A P56704 1/20 0.34
F2R P25116 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KCNH2 Q12809 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177874 0.89 SCD (0.36) LMNAGAACTSSSLC6A2SLC6A4
SCHEMBL7183925 0.88 CTSS (0.33) LMNAGAACTSSSLC6A2SLC6A4
SCHEMBL7183932 0.83 CNR2 (0.39) LMNAGAACTSSSLC6A2SLC6A4
SCHEMBL7189807 0.82 CA2 (0.41) LMNACTSSALDH1A1CTSKF2R
SCHEMBL7185548 0.81 F2R (0.36) GAAALDH1A1HPGDF2RCYP3A4
SCHEMBL7189513 0.81 CTSS (0.39) LMNAGAACTSSTAS2R14CTSK
SCHEMBL7186443 0.80 CNR2 (0.39) LMNAGAAALDH1A1HPGDCYP3A4
SCHEMBL7182608 0.80 CNR2 (0.39) LMNAGAATAS2R14F2RSLC6A3
SCHEMBL7181687 0.79 LMNA (0.40) LMNAGAATAS2R14ALDH1A1CYP3A4
SCHEMBL7187696 0.78 CA12 (0.41) LMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885GAA 4753/4885CTSS 4260/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885GAA 4793/4885CTSS 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.